Purple Book product · Biosimilar 351(k)
Armlupeg
pegfilgrastim-unne
Nov 28, 2025
Approved
Biosimilar 351(k)
License type
Rx
Marketing
1
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Nov 28, 2025
8 mo ago
Today
Pharmaceutical detail
Strength
6MG/0.6ML
Dosage form
Injection
Route
Subcutaneous
Presentation
Pre-Filled Syringe
Center
CDER
License number
2052
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyBiosimilar of pegfilgrastim (Neulasta)
Patent list (1)
| Patent | Expires | In | Source |
|---|---|---|---|
| 9,856,287 | Jun 21, 2030 | in 4 yr | FDA |
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
When do Armlupeg's patents expire?
The FDA Purple Book lists 1 published patent for Armlupeg, with the last listed patent expiring Jun 21, 2030. Every patent below links to its FDA source record so you can verify the expiration date.
Is Armlupeg a biosimilar?
Yes. Armlupeg is a Biosimilar 351(k) referencing pegfilgrastim, licensed under a 351(k) BLA.
Is Armlupeg interchangeable?
Armlupeg is a 351(k) biosimilar but does not carry an interchangeability designation in the Purple Book, so pharmacy-level substitution depends on state law.
What is Armlupeg's BLA number?
Armlupeg is licensed under BLA 761212, held by Lupin Limited (Biotech Division).
When was Armlupeg approved by the FDA?
Armlupeg was approved by the FDA on Nov 28, 2025.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
